Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care?

Future Oncol. 2017 May;13(11):951-953. doi: 10.2217/fon-2017-0050.
No abstract available

Keywords: FOLFIRINOX; pancreatic adenocarcinoma; resectable.

Publication types

  • Editorial

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Adenocarcinoma / surgery
  • Antineoplastic Combined Chemotherapy Protocols
  • Drug Combinations
  • Fluorouracil / therapeutic use*
  • Humans
  • Irinotecan
  • Leucovorin / therapeutic use*
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / surgery
  • Organometallic Compounds / therapeutic use*
  • Oxaliplatin
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / surgery
  • Standard of Care

Substances

  • Drug Combinations
  • Organometallic Compounds
  • folfirinox
  • Oxaliplatin
  • Irinotecan
  • Leucovorin
  • Fluorouracil